Rani Therapeutics Holdings Inc (RANI)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $60.78M
Last updated: Nov 17, 2026 at 4:19 PM ET
Rani Therapeutics Holdings Inc (RANI) Statistics
Rani Therapeutics Holdings (RANI) has a market cap of $60.78M and an enterprise value of $57.16M. Its share count is up 328.49% from a year earlier. It kept -521.20% of revenue as net income over the last 12 months.
Total Valuation
Enterprise value is 5.96% below the market cap, as cash exceeds debt.
| Market Cap | $60.78M |
|---|---|
| Enterprise Value | $57.16M |
| Latest price (Nov 17, 2026) | $0.56 |
Key Dates
The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 25, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 9, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 16.9x and 3.3x. Its year-end P/S ranged from 31.2x to 89.5x from 2023 to 2025.
| P/S Ratio | 16.9x |
|---|---|
| Forward P/S | 9.5x |
| P/B Ratio | 3.3x |
Price Statistics
The stock is down 70.24% over 52 weeks and trades 18.84% below its 50-day average.
| Beta (1Y) | 2.27 |
|---|---|
| 52-Week Change | -70.24% |
| 1-Month Change | -13.98% |
| 3-Month Change | -38.97% |
| 6-Month Change | -36.75% |
| 5-Year Change | -97.43% |
| Total Return (1Y) | -70.24% |
| Total Return (3Y CAGR) | -34.70% |
| Total Return (5Y CAGR) | -56.30% |
| Max Drawdown (1Y) | -73.39% |
| Max Drawdown (3Y) | -94.78% |
| Sharpe Ratio (1Y) | -1.46 |
| Correlation with SPY (1Y) | 0.38 |
| 50-Day Average | $0.69 |
| 200-Day Average | $0.89 |
| 52-Week Range | $0.50 to $1.91 |
| RSI (14 Days) | 41.5 |
| Average Volume (20 Days) | 514.57K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.26x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.26x |
|---|---|
| Quick Ratio | 5.26x |
| Debt / Equity | 0.00x |
| Interest Coverage | -32.92x |
Returns and Efficiency
Return on equity is -101.01% and return on assets is -65.33% over the last 12 months.
| Return on Equity (ROE) | -101.01% |
|---|---|
| Return on Assets (ROA) | -65.33% |
| ROA (5Y Average) | -88.58% |
| Asset Turnover | 0.21x |
| Receivables Turnover | 3.29x |
Scores
RANI has an Altman Z-Score of 0.68, in the distress zone below 1.81, and a Piotroski F-Score of 3 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 0.68 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 3 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $6.58M over the last 12 months is up 448.67% from the 12 months before.
| Revenue | $6.58M |
|---|---|
| Revenue Growth (YoY) | +448.67% |
| Gross Profit | $6.58M |
| Operating Income | -$34.92M |
| Pretax Income | -$34.32M |
| Net Income | -$34.32M |
| EBITDA | -$33.69M |
| Reported EPS (TTM) | -$0.19 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 64.67% of the $52.53M in total assets.
| Cash and Equivalents | $3.62M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.62M |
| Net Cash Per Share | $0.02 |
| Working Capital | $39.25M |
| Shareholder Equity | $33.97M |
| Book Value Per Share | $0.17 |
| Total Assets | $52.53M |
| Total Liabilities | $11.18M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $230.00K of capital spending, operating cash flow left -$23.22M of free cash flow.
| Operating Cash Flow | -$22.99M |
|---|---|
| Capital Expenditures | $230.00K |
| Free Cash Flow | -$23.22M |
| FCF Per Share | -$0.20 |
| Depreciation and Amortization | $2.43M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -530.45%.
| Gross Margin | 100.00% |
|---|---|
| Operating Margin | -530.45% |
| Pretax Margin | -521.20% |
| Net Margin | -521.20% |
| EBITDA Margin | -511.71% |
| FCF Margin | -352.67% |
Growth
| Revenue Growth (5Y CAGR) | +28.73% |
|---|---|
| Book Value Per Share Growth (2Y CAGR) | -32.82% |
| Tangible Book Per Share Growth (2Y CAGR) | -32.82% |
Dividends and Yields
RANI does not pay a dividend.
| Buyback Yield | -61.23% |
|---|---|
| Shareholder Yield | -61.23% |
Peer Position
Against 6 similar companies, RANI has the 6th highest P/S.
P/S RatioPeer median 33.3x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -13.92%
| P/S Ratio | 16.9x vs 33.3x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +448.67% vs -13.92% median |
Analyst Forecast
Consensus estimates put revenue growth at 85.94% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +85.94% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About RANI
What is RANI's market cap?
Rani Therapeutics Holdings has a market cap of $60.78M. Its enterprise value, which adds debt and subtracts cash, is $57.16M.
How many shares of RANI are outstanding?
Rani Therapeutics Holdings has 199.01M shares outstanding. The count is up 328.49% from a year earlier.
Does RANI pay a dividend?
No. Rani Therapeutics Holdings does not pay a dividend.
How much debt does RANI have?
Rani Therapeutics Holdings has $0 of total debt and $3.62M of cash and equivalents, a net cash position of $3.62M.
RANI pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors